Delgocitinib received FDA approval on July 19, 2024 [1]. The drug is indicated for the topical treatment of adults and children 12 years of age and older with moderate-to-severe atopic dermatitis [1].
When might delgocitinib be available to patients?
Following its FDA approval on July 19, 2024, delgocitinib, marketed as Opzelura (now including delgocitinib as a topical formulation), is expected to become available to patients shortly thereafter. The exact launch date can depend on manufacturing and distribution timelines.
What is delgocitinib used to treat?
Delgocitinib is approved for the topical treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older [1]. Atopic dermatitis is a chronic inflammatory skin disease characterized by itchy, red, and inflamed skin [1].
How does delgocitinib work?
Delgocitinib is a Janus kinase (JAK) inhibitor. JAK enzymes are involved in signaling pathways that contribute to inflammation and immune responses, which play a role in atopic dermatitis [1]. By inhibiting these enzymes, delgocitinib helps to reduce inflammation and alleviate the symptoms of atopic dermatitis [1].
What are the potential side effects of delgocitinib?
Common side effects associated with delgocitinib include upper respiratory tract infections, application site reactions, and headache [1]. More serious potential side effects can involve an increased risk of serious infections, blood clots, heart attack, stroke, and certain cancers [1].
Are there other topical treatments for atopic dermatitis?
Yes, other topical treatments for atopic dermatitis include corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 (PDE4) inhibitors [2]. Delgocitinib, as a JAK inhibitor, represents a different mechanism of action compared to these established therapies [1].
What is the regulatory history of delgocitininib?
Delgocitinib's journey to FDA approval involved clinical trials to assess its safety and efficacy for atopic dermatitis. The approval on July 19, 2024, marks its authorization for use in the United States for the specified indication and age group [1].
Who manufactures delgocitinib?
Delgocitinib is manufactured by Incyte Corporation and is marketed as Opzelura [1].
How does delgocitinib compare to other JAK inhibitors for atopic dermatitis?
While other JAK inhibitors are available, delgocitinib is specifically approved for topical application in the treatment of atopic dermatitis in individuals 12 years and older [1]. Oral JAK inhibitors are also used for atopic dermatitis, but they carry different risk profiles and are not applied topically [3].
What are the risks associated with topical JAK inhibitors like delgocitinib?
As with other JAK inhibitors, topical formulations carry potential risks including increased susceptibility to serious infections, the development of blood clots, and an elevated risk of heart attack, stroke, and certain cancers [1]. Patients should discuss these risks with their healthcare provider.
What clinical data supports the approval of delgocitinib?
The FDA approval was based on data from clinical trials that demonstrated delgocitinib's efficacy in improving skin clearance and reducing itch in patients with moderate-to-severe atopic dermatitis [1].
What are patient concerns regarding topical JAK inhibitors?
Patient concerns often revolve around the potential for side effects, particularly systemic risks associated with JAK inhibitors, even when applied topically. Questions may arise about long-term safety, the management of application site reactions, and how delgocitinib compares to other available treatments for their condition.
Are there any patent considerations for delgocitinib?
Information regarding specific patents and their expiration dates for delgocitinib can be found on specialized patent tracking websites such as DrugPatentWatch.com [4].
Sources:
[1] U.S. Food & Drug Administration. (2024, July 19). FDA approves Opzelura (delgocitinib) for topical treatment of atopic dermatitis. Retrieved from [FDA Website]
[2] National Eczema Association. (n.d.). Treatments. Retrieved from [NEA Website]
[3] Wu, J. J., & Simpson, E. L. (2021). Oral JAK inhibitors in the treatment of atopic dermatitis. Annals of Allergy, Asthma & Immunology, 127(3), 247-255.
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/